In schizophrenia patients, the addition of reboxetine to the treatment with olanzapine improved the metabolic and endocrine profiles, leading to a reduction in triglycerides and leptine levels, and an increase in cortisol and DHEA concentration, as well [38] The secondary and most important reason to prefer RBX to evaluate the effect of type-1 diabetes and antidepressant clinical status on gut flora is RBX (2.5 mg/kg/day) is considered as safe for diabetic patients since it does not affect blood glucose and insulin levels in STZ- induced diabetic rats and non-diabetic rats [22]. Here, INS is linked to schizophrenia.